Patents Assigned to Tetragenetics, Inc.
  • Anti-Kv1.3 antibodies, and methods of production and use thereof
    Patent number: 11597763
    Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: March 7, 2023
    Assignee: Tetragenetics, Inc.
    Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini, Alka Agrawal
  • ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF
    Publication number: 20190144538
    Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
    Type: Application
    Filed: May 2, 2017
    Publication date: May 16, 2019
    Applicant: Tetragenetics, Inc.
    Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini
  • Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor
    Patent number: 9512181
    Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production of immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Granule lattice protein/Antigen(Grl/Ag) fusion polypeptides.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: December 6, 2016
    Assignee: Tetragenetics, Inc.
    Inventors: Theodore G. Clark, Yelena Bisharyan, Ashot Papoyan, Kyle Anderson, Paul Colussi
  • FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS, GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR
    Publication number: 20150125483
    Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Grl/Ag fusion polypeptides.
    Type: Application
    Filed: May 29, 2012
    Publication date: May 7, 2015
    Applicant: Tetragenetics, Inc.
    Inventors: Theodore G. Clark, Yelena Bisharyan, Ashot Papoyan, Kyle Anderson, Paul Colussi
  • Production of recombinant proteins in ciliates and uses thereof
    Patent number: 8722361
    Abstract: This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production and purification of recombinant proteins in ciliates.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: May 13, 2014
    Assignees: Tetragenetics, Inc., The University of Chicago
    Inventors: Theodore G. Clark, Ashot Papoyan, Aaron Turkewitz
  • Polypeptide expression in ciliates
    Patent number: 8664374
    Abstract: This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production of recombinant polypeptides in ciliates.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Tetragenetics, Inc.
    Inventors: Paul Colussi, Donna Cassidy-Hanley, Theodore G. Clark